Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Decreased Levels of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Therapy Correlate with Responsiveness to Subsequent Biologic Treatments in Axial Spondyloarthritis Patients

  • By

  • Addison Pacheco

  • Patricia Remalante-Rayco

  • Nigil Haroon

  • Denis Poddubnyy

  • Robert D. Inman

  • August 29, 2026

Share

Original Source(s)

Related Content